autologous tumor cells + dendritic cells

This therapy is a personalized cancer immunotherapy that combines autologous (patient-derived) dendritic cells with antigens from the patient's own tumor cells. Dendritic cells are collected from the patient’s blood and loaded ex vivo with antigens derived from self-renewing or lysed autologous tumor cells. The resulting product is administered to the patient, often suspended in granulocyte-macrophage colony-stimulating factor (GM-CSF), via subcutaneous injection. The mechanism of action involves priming and activating T lymphocytes—especially Th1/Th17 responses—against a broad array of unique, patient-specific tumor-associated antigens, thereby inducing an immune response targeting residual or metastatic cancer. This approach has been studied in various cancers including melanoma, glioblastoma, ovarian cancer, hepatocellular carcinoma, and renal cell carcinoma[1][2][4]. Clinical studies have shown that this therapy can be well-tolerated and may result in durable complete regressions or improved survival in some patients.

Other names

autologous dendritic cell vaccine loaded with autologous tumor antigensDC-ATAdendritic cell-autologous tumor antigen vaccine